Comparison of Methods for Monitoring the Body Condition of Dairy Cows

Dairy cows are known to mobilize body fat to achieve their genetic potential for milk production, which can have a detrimental impact on the health, fertility and survival of the cow. Better monitoring of cows with poor body condition (low or high body fat) will lead to improvements in production efficiencies and less wasted resources when producing milk from dairy cows. The aim of this study was to compare different methods for monitoring the body condition (body fat) of dairy cows. The methods used to measure body condition were: ultrasound scanner, manual observation, and a still digital image of the cow. For comparison, each measure was expressed as a body condition score (BCS) on a scale of extremely thin (1) to very fat (5) in quarter intervals. A total of 209 cows at various stages of lactation were assessed. Lin's concordance correlation coefficient (CCC) and the root mean square prediction error (RMSPE) were used to compare the accuracy of methods. The average BCS across cows was 2.10 for ultrasound, 2.76 for manual and 2.41 for digital methods. The study found that both manual (r = 0.790) and digital (r = 0.819) approaches for monitoring cow body condition were highly correlated with ultrasound BCS measurements. After adjusting correlation coefficients for prediction bias relative to a 45° line through the origin, the digital BCS had a higher CCC of 0.789 when compared to the ultrasound BCS than the manual BCS with a CCC of 0.592. The digital BCS also had a lower prediction error (RMSPE = 28.3%) when compared with ultrasound BCS than the manual BCS (RMSPE = 42.7%). The prediction error for digital and manual BCS methods were similar for cows with a BCS of 2.5 or more (RMSPE = 20.5 and 19.0%, respectively) but digital BCS was more accurate for cows of < 2.5 BCS (RMSPE = 35.5 and 63.8%, respectively). Digital BCS can provide a more accurate assessment of cow body fat than manual BCS observations, with the added benefit of more automated and frequent monitoring potentially improving the welfare and sustainability of high production systems

Tuberculosis in badgers where the bovine tuberculosis epidemic is expanding in cattle in England.

Bovine tuberculosis (bTB) is an important animal health and economic problem for the cattle industry and a potential zoonotic threat. Wild badgers (Meles meles) play a role on its epidemiology in some areas of high prevalence in cattle, particularly in the UK and Republic of Ireland and increasingly in parts of mainland Europe. However, little is known about the involvement of badgers in areas on the spatial edge of the cattle epidemic, where increasing prevalence in cattle is seen. Here we report the findings of a study of found-dead (mainly road-killed) badgers in six counties on the edge of the English epidemic of bTB in cattle. The overall prevalence of Mycobacterium tuberculosis complex (MTC) infection detected in the study area was 51/610 (8.3%, 95% CI 6.4-11%) with the county-level prevalence ranging from 15 to 4-5%. The MTC spoligotypes of recovered from badgers and cattle varied: in the northern part of the study area spoligotype SB0129 predominated in both cattle and badgers, but elsewhere there was a much wider range of spoligotypes found in badgers than in cattle, in which infection was mostly with the regional cattle spoligotype. The low prevalence of MTC in badgers in much of the study area, and, relative to in cattle, the lower density of sampling, make firm conclusions difficult to draw. However, with the exception of Cheshire (north-west of the study area), little evidence was found to link the expansion of the bTB epidemic in cattle in England to widespread badger infection

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials

Effect of dairy breed and peri-natal live weight on; feed intake, live weight gain, feed efficiency and bio-economic viability of a high milk feeding system for rearing bull calves

An estimated 101, 959 UK dairy bull calves were euthanized in 2016, mainly due to a lack of profitable bull beef schemes, particularly for the smaller Jersey crossbreed calves. This study aimed to compare the performance of Holstein Friesian and Jersey cross Holstein Friesian breeds, by allocating 60 calves into pairs (n=30) at 10 (± 3) d of age, according to breed and initial live weight (ILW) to one of three groups: Holstein Friesian (HF) of higher ILW (50 ± 0.9 kg); Jersey x HF of higher (JxH) ILW (51 ± 0.9 kg) and Jersey x HF of lower (JxL) ILW (44.1 ± 0.8). All calves were offered milk replacer (MR) at ≤ 10 L/d (MR: 150 g FM/L), which was offered via teat buckets twice daily, along with ad libitum access to cereal based starter, straw and water. Calves were all weaned at 12 weeks of age. Dairy breed and ILW had no effect on pre and post-weaning growth rates, total milk and feed efficiency. Pre-weaning starter consumption was lower for JL compared HF and JH. Initial LW, weaning and post weaning LW were greater, while the number of days taken to reach a LW of 120 kg was 7 d less for HF and JxH compared with JxL calves. It was concluded that, in terms of LW at 10 ± 3 d of age, larger (≥ 50 kg) HF and JxH calves were equally viable, while smaller (< 50 kg) JxL calves could potentially be equally viable at a lower purchase price

Effect of dairy breed and peri-natal live weight on; feed intake, live weight gain, feed efficiency and bio-economic viability of a high milk feeding system for rearing bull calves

An estimated 101, 959 UK dairy bull calves were euthanized in 2016, mainly due to a lack of profitable bull beef schemes, particularly for the smaller Jersey crossbreed calves. This study aimed to compare the performance of Holstein Friesian and Jersey cross Holstein Friesian breeds, by allocating 60 calves into pairs (n=30) at 10 (± 3) d of age, according to breed and initial live weight (ILW) to one of three groups: Holstein Friesian (HF) of higher ILW (50 ± 0.9 kg); Jersey x HF of higher (JxH) ILW (51 ± 0.9 kg) and Jersey x HF of lower (JxL) ILW (44.1 ± 0.8). All calves were offered milk replacer (MR) at ≤ 10 L/d (MR: 150 g FM/L), which was offered via teat buckets twice daily, along with ad libitum access to cereal based starter, straw and water. Calves were all weaned at 12 weeks of age. Dairy breed and ILW had no effect on pre and post-weaning growth rates, total milk and feed efficiency. Pre-weaning starter consumption was lower for JL compared HF and JH. Initial LW, weaning and post weaning LW were greater, while the number of days taken to reach a LW of 120 kg was 7 d less for HF and JxH compared with JxL calves. It was concluded that, in terms of LW at 10 ± 3 d of age, larger (≥ 50 kg) HF and JxH calves were equally viable, while smaller (< 50 kg) JxL calves could potentially be equally viable at a lower purchase price